Management of Localized Prostate Cancer in Elderly Patients
Yıl: 2022 Cilt: 21 Sayı: 3 Sayfa Aralığı: 73 - 79 Metin Dili: İngilizce DOI: 10.4274/uob.galenos.2022.2022.2.1 İndeks Tarihi: 14-05-2023
Management of Localized Prostate Cancer in Elderly Patients
Öz: There are uncertainties concerning treatment management in elderly patients diagnosed with localized prostate cancer. The patient’s age and morbidity are the most important factors affecting the treatment to be applied. Many screening scales are used for this purpose. It is reported that standard definitive treatments are suitable for patients with a life expectancy of more than 10 years, who are considered fit according to these screening scales. However, treatment options should be discussed in detail with patients in this group, which are already old and getting older. Therefore, elderly patients can be considered as the group that should be given the most information about the side effects of treatments. It is very important to properly evaluate the current state of the patient prior to treatment and inform them well to ensure that they have more rational expectations.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-249.
- 2. National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). Cancer stat facts: Prostate Cancer. Available from: https://seer.cancer.gov/statfacts/html/prost.html (cited 20.11.2018)
- 3. United States Census Bureau. Projections of the populations of the United States: 1982 to 2050 (advance report). Available from: https:// www.census.gov/content/dam/Census/library/publications/1982/ demo/p25-922.pdf (cited 20.11.2018)
- 4. Droz JP, Boyle H, Albrand G, et al. Role of Geriatric Oncologists in Optimizing Care of Urological Oncology Patients. Eur Urol Focus 2017;3:385-394.
- 5. Droz JP, Balducci L, Bolla M, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010;73:68-91.
- 6. Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2017;9:CD006211.
- 7. Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012;23:2166-2172.
- 8. Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol 2015;26:288-300.
- 9. Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One 2014;9:e115060.
- 10. Şen V, Yıldız A, Bozkurt O, et al. Turkish Linguistic Validation of the Geriatric 8 Screening Tool. Bull Urooncol 2021;20:133-137.
- 11. Droz JP, Albrand G, Gillessen S, et al. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. Eur Urol 2017;72:521-531.
- 12. Chan CC, Fage BA, Burton JK, et al. Mini-Cog for the detection of dementia within a secondary care setting. Cochrane Database Syst Rev 2021;7:CD011414.
- 13. Boyle HJ, Alibhai S, Decoster L, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 2019;116:116-136.
- 14. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTROESUR- SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2021;79:243-262.
- 15. Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011;29:1335-1341.
- 16. Groome PA, Rohland SL, Siemens DR, et al. Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates. Cancer 2011;117:3943-3952.
- 17. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008;26:54-59.
- 18. Kirkhus L, Jordhøy M, Šaltytė Benth J, et al. Comparing comorbidity scales: Attending physician score versus the Cumulative Illness Rating Scale for Geriatrics. J Geriatr Oncol 2016;7:90-98.
- 19. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-1251.
- 20. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000;36:453-471.
- 21. D’Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376-1383.
- 22. Bruinsma SM, Roobol MJ, Carroll PR, et al. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. Nat Rev Urol 2017;14:312-322.
- 23. Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015;33:272-277.
- 24. Albertsen PC. Observational studies and the natural history of screendetected prostate cancer. Curr Opin Urol 2015;25:232-237.
- 25. Trinh QD, Schmitges J, Sun M, et al. Open radical prostatectomy in the elderly: a case for concern? BJU Int 2012;109:1335-1340.
- 26. Ranasinghe W, Wang LL, Persad R, et al. Survival outcomes in elderly men undergoing radical prostatectomy in Australia. ANZ J Surg 2018;88:E189-E193.
- 27. Scosyrev E, Wu G, Mohile S, Messing EM. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer 2012;118:5768-5776.
- 28. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011;29:235-241.
- 29. Löffeler S, Halland A, Fawad H, et al. Non-metastatic prostate cancer: rationale for conservative treatment and impact on disease-related morbidity and mortality in the elderly. Scand J Urol 2020;54:105-109.
- 30. King JC, Zenati M, Steve J, et al. Deviations from Expected Treatment of Pancreatic Cancer in Octogenarians: Analysis of Patient and Surgeon Factors. Ann Surg Oncol 2016;23:4149-4155.
- 31. Adejoro O, Gupta P, Ziegelmann M, et al. Effect of minimally invasive radical prostatectomy in older men. Urol Oncol 2016;34:234.e1-11.
- 32. Kumar A, Samavedi S, Bates AS, et al. Age stratified comparative analysis of perioperative, functional and oncologic outcomes in patients after robot assisted radical prostatectomy--A propensity score matched study. Eur J Surg Oncol 2015;41:837-843.
- 33. Iguchi K, Tanaka T, Minami A, et al. Characteristics of urodynamic study parameters associated with intermediate-term continence after robot-assisted radical prostatectomy in elderly patients. Aging Male 2020;23:1039-1045.
- 34. Asil E, Yıldızhan M, Koç E, et al. Robot Assisted Radical Prostatectomy in Elderly Patients Older than 70 Years Old: Operative, Oncologic and Functional Outcomes. Van Med J 2021;28:9-14.
- 35. Tavukçu HH, Kaplan M. Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. Bull Urooncol 2021;20:73-82.
- 36. Ficarra V, Novara G, Rosen RC, et al. Systematic review and metaanalysis of studies reporting urinary continence recovery after robotassisted radical prostatectomy. Eur Urol 2012;62:405-417.
- 37. Mandel P, Graefen M, Michl U, et al. The effect of age on functional outcomes after radical prostatectomy. Urol Oncol 2015;33:203. e11-18.
- 38. Shikanov S, Desai V, Razmaria A, et al. Robotic radical prostatectomy for elderly patients: probability of achieving continence and potency 1 year after surgery. J Urol 2010;183:1803-1807.
- 39. Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005;97:1525-1532.
- 40. Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014;12:686-718.
- 41. Mandel P, Chandrasekar T, Chun FK, et al. Radical prostatectomy in patients aged 75 years or older: review of the literature. Asian J Androl 2017;21:32-36.
- 42. Porres D, Pfister D, Labanaris AP, et al. Robot-assisted radical prostatectomy in elderly patients: surgical, oncological and functional outcomes. Urologe A 2012;51:1424-1431.
- 43. Sokolov EA, Veliev EI, Veliev RA. [Feasibility and risks of nerve-sparing technique of radical prostatectomy in elderly patients]. Urologiia 2021;2:57-61.
- 44. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostatespecific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002;20:3376-3385.
- 45. Wilson JM, Dearnaley DP, Syndikus I, et al. The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. Int J Radiat Oncol Biol Phys 2018;100:1179-1189.
- 46. Yamazaki H, Masui K, Suzuki G, et al. Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer - Brachytherapy enhanced late GU toxicity especially in elderly. Clin Transl Radiat Oncol 2020;25:67-74.
| APA | Keten T, güzel ö, Atan A (2022). Management of Localized Prostate Cancer in Elderly Patients. , 73 - 79. 10.4274/uob.galenos.2022.2022.2.1 |
| Chicago | Keten Tanju,güzel özer,Atan Ali Management of Localized Prostate Cancer in Elderly Patients. (2022): 73 - 79. 10.4274/uob.galenos.2022.2022.2.1 |
| MLA | Keten Tanju,güzel özer,Atan Ali Management of Localized Prostate Cancer in Elderly Patients. , 2022, ss.73 - 79. 10.4274/uob.galenos.2022.2022.2.1 |
| AMA | Keten T,güzel ö,Atan A Management of Localized Prostate Cancer in Elderly Patients. . 2022; 73 - 79. 10.4274/uob.galenos.2022.2022.2.1 |
| Vancouver | Keten T,güzel ö,Atan A Management of Localized Prostate Cancer in Elderly Patients. . 2022; 73 - 79. 10.4274/uob.galenos.2022.2022.2.1 |
| IEEE | Keten T,güzel ö,Atan A "Management of Localized Prostate Cancer in Elderly Patients." , ss.73 - 79, 2022. 10.4274/uob.galenos.2022.2022.2.1 |
| ISNAD | Keten, Tanju vd. "Management of Localized Prostate Cancer in Elderly Patients". (2022), 73-79. https://doi.org/10.4274/uob.galenos.2022.2022.2.1 |
| APA | Keten T, güzel ö, Atan A (2022). Management of Localized Prostate Cancer in Elderly Patients. Üroonkoloji Bülteni, 21(3), 73 - 79. 10.4274/uob.galenos.2022.2022.2.1 |
| Chicago | Keten Tanju,güzel özer,Atan Ali Management of Localized Prostate Cancer in Elderly Patients. Üroonkoloji Bülteni 21, no.3 (2022): 73 - 79. 10.4274/uob.galenos.2022.2022.2.1 |
| MLA | Keten Tanju,güzel özer,Atan Ali Management of Localized Prostate Cancer in Elderly Patients. Üroonkoloji Bülteni, vol.21, no.3, 2022, ss.73 - 79. 10.4274/uob.galenos.2022.2022.2.1 |
| AMA | Keten T,güzel ö,Atan A Management of Localized Prostate Cancer in Elderly Patients. Üroonkoloji Bülteni. 2022; 21(3): 73 - 79. 10.4274/uob.galenos.2022.2022.2.1 |
| Vancouver | Keten T,güzel ö,Atan A Management of Localized Prostate Cancer in Elderly Patients. Üroonkoloji Bülteni. 2022; 21(3): 73 - 79. 10.4274/uob.galenos.2022.2022.2.1 |
| IEEE | Keten T,güzel ö,Atan A "Management of Localized Prostate Cancer in Elderly Patients." Üroonkoloji Bülteni, 21, ss.73 - 79, 2022. 10.4274/uob.galenos.2022.2022.2.1 |
| ISNAD | Keten, Tanju vd. "Management of Localized Prostate Cancer in Elderly Patients". Üroonkoloji Bülteni 21/3 (2022), 73-79. https://doi.org/10.4274/uob.galenos.2022.2022.2.1 |
